scholarly journals Prospective Study of Prostate Tumor Angiogenesis and Cancer-Specific Mortality in the Health Professionals Follow-Up Study

2009 ◽  
Vol 27 (33) ◽  
pp. 5627-5633 ◽  
Author(s):  
Lorelei A. Mucci ◽  
Anna Powolny ◽  
Edward Giovannucci ◽  
Zhiming Liao ◽  
Stacey A. Kenfield ◽  
...  

Purpose Tumor growth requires the development of independent vascular networks that are often primitive in morphology and function. We examined whether microvessel morphology contributes to the considerable biologic heterogeneity of prostate cancer. Methods We evaluated microvessel morphology as a predictor of prostate cancer mortality among 572 men in the Health Professionals Follow-Up Study diagnosed with cancer during 1986 to 2000. We immunostained prostatectomy tumor block sections for endothelial marker CD34 and assessed microvessel density, vessel size (area and diameter), and irregularity of vessel lumen using image analysis. Proportional hazards models were used to assess microvessel density and morphology in relation to lethal prostate cancer. Results Poorly differentiated tumors exhibited greater microvessel density, greater irregularity of the vessel lumen, and smaller vessels. During 20 years of follow-up, 44 men developed bone metastases or died of cancer. Men with tumors exhibiting the smallest vessel diameter, based on quartiles, were 6.0 times more likely (95% CI, 1.8 to 20.0) to develop lethal prostate cancer. Men with the most irregularly shaped vessels were 17.1 times more likely (95% CI, 2.3 to 128) to develop lethal disease. Adjusting for Gleason grade and prostate-specific antigen levels did not qualitatively change the results. Microvessel density was not linked to cancer-specific mortality after adjusting for clinical factors. Conclusion Aggressive tumors form vessels that are primitive in morphology and function, with consequences for metastases. Vascular size and irregularity reflect the angiogenic potential of prostate cancer and may serve as biomarkers to predict prostate cancer mortality several years after diagnosis.

2016 ◽  
Vol 183 (3) ◽  
pp. 210-217 ◽  
Author(s):  
Cindy Ke Zhou ◽  
Paul H. Levine ◽  
Sean D. Cleary ◽  
Heather J. Hoffman ◽  
Barry I. Graubard ◽  
...  

2015 ◽  
Vol 137 (4) ◽  
pp. 949-958 ◽  
Author(s):  
Elizabeth A. Platz ◽  
Charles G. Drake ◽  
Kathryn M. Wilson ◽  
Siobhan Sutcliffe ◽  
Stacey A. Kenfield ◽  
...  

2019 ◽  
Vol 2 (2) ◽  
pp. 126-134 ◽  
Author(s):  
Mary K. Downer ◽  
Christopher B. Allard ◽  
Mark A. Preston ◽  
Kathryn M. Wilson ◽  
Stacey A. Kenfield ◽  
...  

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 62-62
Author(s):  
Brandon Arvin Virgil Mahal ◽  
Ayal Aaron Aizer ◽  
Jason Alexander Efstathiou ◽  
Paul Linh Nguyen

62 Background: It has been hypothesized that very low PSAs in men with high-grade prostate cancer could reflect dedifferentiation and a poorer prognosis, but clinical evidence to support this is limited. We sought to determine whether a very low-presenting PSA was associated with greater prostate cancer-specific mortality (PCSM) among men with Gleason score (GS) 8-10 disease. Methods: The Surveillance, Epidemiology and End Results Program was used to identify a national cohort of 328,904 men diagnosed with cT1-4N0M0 prostate cancer between 2004 and 2010. Multivariable Fine-Gray competing-risks regression analysis was used to determine PCSM as a function of PSA level (<2.5 ng/mL, 2.6-4 ng/mL, 4.1-10 ng/mL, 10.1-20 ng/mL, 20.1-40 ng/mL, or >40ng/mL) and GS (8-10 vs. <=7). Results: Median follow-up was 38 months. Among men with GS 8-10 disease, using PSA 4.1-10 as the reference group, the Adjusted HR (AHR) for PCSM for men with PSA level <2.5 was 1.86 (95% CI 1.51-2.29; P<0.001), PSA 2.6-4 was1.44 (1.17-1.78; P<0.001), PSA 10.1-20 was 1.58 (1.39-1.78; P<0.001), PSA 20.1-40 was 2.04 (1.78-2.33; P<0.001), and PSA>40 was 3.19 (2.83-3.59; P<0.001), suggesting a U-shaped distribution. There was a significant interaction between PSA level and GS (Pinteraction<0.001) such that PSA <2.5 only significantly predicted for poorer PCSM among patients with high grade GS 8-10 disease. Conclusions: Among patients with high grade GS 8-10 disease, patients with PSA <2.5 and 2.6-4 appear to have a higher risk for cancer-specific death compared to patients with a 10.1-20 PSA level, supporting the notion that low PSA in GS 8-10 disease may be a sign of underlying aggressive and extremely poorly differentiated or anaplastic low PSA-producing tumors. Patients with low PSA GS 8-10 disease should be considered for clinical trials studying the use of chemotherapy and other novel agents in very-high risk prostate cancers.


2010 ◽  
Vol 128 (3) ◽  
pp. 660-667 ◽  
Author(s):  
Katharina Nimptsch ◽  
Elizabeth A. Platz ◽  
Michael N. Pollak ◽  
Stacey A. Kenfield ◽  
Meir J. Stampfer ◽  
...  

PLoS ONE ◽  
2014 ◽  
Vol 9 (5) ◽  
pp. e94683 ◽  
Author(s):  
Marcelo Chen ◽  
Yi-Ling Huang ◽  
Yu-Chuen Huang ◽  
Irene M. Shui ◽  
Edward Giovannucci ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document